Cellectis的现成CAR-T疗法显示,复发淋巴瘤病人有很强的结果,计划在2026年进入新的试验阶段。 Cellectis' off-the-shelf CAR-T therapy showed strong results in relapsed lymphoma patients, with plans for a new trial phase in 2026.

Cellectis报告了其现有两套CAR-T疗法的试验结果更新后第一阶段的试验结果,显示在8名已接受过包括CD19 CAR-T疗法在内的先前治疗的复发或复发性非Hodgkin淋巴瘤患者中,总体回应率为88%,完全回应率为63%。 Cellectis reported updated Phase 1 trial results for its off-the-shelf dual CAR-T therapy eti-cel, showing an 88% overall response rate and 63% complete response rate in eight patients with relapsed or refractory non-Hodgkin lymphoma who had prior treatments, including CD19 CAR-T therapy. 临床数据表明,低剂量的IL-2可能增加CAR-T细胞的持久性,而不会增加毒性。 Preclinical data suggest low-dose IL-2 may boost CAR-T cell persistence without increasing toxicity. 该公司计划在2026年初开始一个新的IL-2支助组群,预计到2026年将获得完整的第一阶段数据。 The company plans to begin a new IL-2 support cohort in early 2026, with full Phase 1 data expected in 2026.